Research programme: anti-RON monoclonal antibodies - Eli Lilly

Drug Profile

Research programme: anti-RON monoclonal antibodies - Eli Lilly

Alternative Names: IMC-41A10; Ron MAb; RON-1; RON-6

Latest Information Update: 27 Mar 2009

Price : $50

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Monoclonal antibodies
  • Mechanism of Action RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Apr 2008 Preclinical pharmacodynamics data in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
  • 04 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section
  • 08 Feb 2005 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top